Literature DB >> 6725478

Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography.

P J Wedlund, B J Sweetman, C B McAllister, R A Branch, G R Wilkinson.   

Abstract

A gas chromatographic method was developed for the determination of the R- and S- enantiomers of the anticonvulsant, mephenytoin, and its N-demethylated metabolite, 5-phenyl-5- ethylhydantoin ( PEH ), in plasma and blood. Direct enantiomeric separation of mephenytoin and its internal standard was obtained using a chiral capillary column ( Chirasil -Val) followed by nitrogen specific detection. However, resolution of the enantiomers of PEH and its internal standard required propylation at the 3-position of the hydantoin ring prior to analysis. Similar linear and reproducible standard curves were obtained from both plasma and blood over the concentration range 50 ng/ml to 5 micrograms/ml, and above 100 ng/ml the reproducibility was less than 8% (coefficient of variation). Pronounced stereoselective differences in the plasma concentration--time curves for both mephenytoin and PEH were observed in a normal subject who received a single oral dose of 300 mg racemic mephenytoin. The peak plasma level of S-mephenytoin was only one-fifth that of the R-enantiomer and its elimination half-life was less than 3 h compared to over 70 h for R-mephenytoin. Similarly, S- PEH levels were barely detectable whereas concentrations of R-metabolite steadily increased over 4-6 days before slowly declining.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725478     DOI: 10.1016/s0378-4347(00)84078-5

Source DB:  PubMed          Journal:  J Chromatogr


  13 in total

1.  Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease.

Authors:  O Gudjonsson; E Sanz; G Alván; S M Aquilonius; J Reviriego
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers.

Authors:  G Movin-Osswald; A L Nordström; M Hammarlund-Udenaes; A Wahlén; L Farde
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 3.  Chromatographic separation of enantiomers.

Authors:  K G Feitsma; B F Drenth
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

4.  Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.

Authors:  J Reviriego; L Bertilsson; J A Carrillo; A Llerena; M J Valdivielso; J Benítez
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Mephenytoin stereoselective elimination in the rat: I. Enantiomeric disposition following intravenous administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jul-Sep       Impact factor: 2.441

6.  Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

7.  Mephenytoin stereoselective elimination in the rat: III. Stereoselective time course of induction during chronic hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

8.  Rapid isolation of some antiepileptic hydantoins and their analogues with Sep-Pak C18 cartridges and capillary gas chromatography with splitless injection.

Authors:  T Kumazawa; O Suzuki; H Seno; Y Ishikawa; H Hattori
Journal:  Z Rechtsmed       Date:  1990

Review 9.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

10.  Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.

Authors:  Karin Hellman; Ewa Roos; Anna Osterlund; Anneli Wahlberg; Lars L Gustafsson; Leif Bertilsson; Sten Fredrikson
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.